[Thoracic electrical impedance tomography: Technical aspects and clinical applications] [0.03%]
[胸部电阻抗断层扫描技术及临床应用]
N Mazellier,C Roussel,P-A Roger et al.
N Mazellier et al.
Thoracic Electrical Impedance Tomography (EIT) is a functional respiratory imaging technique first developed in the 1970s. It provides real-time functional information at the patient's bedside, without ionizing radiation. Its growing intere...
[Sertraline-induced acute eosinophilic pneumonia: When a side effect becomes a clinical case] [0.03%]
[舍曲林所致急性嗜酸性肺炎：当不良反应成为临床病例]
L Brichard,C Stavart,J El Hayeck et al.
L Brichard et al.
Introduction: Eosinophilic lung disease encompasses a group of diffuse pulmonary parenchymal diseases characterized by eosinophilic infiltration, either localized or associated with a systemic process. Acute eosinophilic ...
[Use of fluticasone/umeclidinium/vilanterol in France: A population based study] [0.03%]
法国布地奈德/乌美溴铵/维兰特罗的使用情况：一项基于人口的研究
B Aguilaniu,J Cittee,L Watier et al.
B Aguilaniu et al.
Introduction: In France, the fixed combination fluticasone/umeclidinium/vilanterol (FF/UMEC/VI) is prescribed for the treatment of moderate to severe COPD in adults not adequately treated by LABA/LAMA or ICS/LABA dual the...
[Does nebulization present a risk of viral transmission? A narrative review] [0.03%]
雾化治疗存在病毒传播风险吗？一项叙述性综述
C Thibon,L Vecellio,J-C Dubus et al.
C Thibon et al.
Nebulization is a commonly applied therapy for patients with respiratory conditions, encompassing those infected with respiratory viruses such as SARS-CoV-2, influenza and RSV. Since the COVID-19 pandemic occurred, concerns have arisen rega...
[The impact of bronchoalveolar lavage in patients intubated for COVID-19] [0.03%]
支气管肺泡灌洗在新冠患者有创机械通气中的作用分析
L A Pernaut,F Wallyn,X Dhalluin et al.
L A Pernaut et al.
Introduction: Pulmonary infections complicating COVID-19 are common. The aim of this study was to describe the main findings regarding the impact of bronchoalveolar lavage (BAL) in severe COVID-19 patients in intensive ca...
[Influence of smoking on the efficacy of immunotherapy in advanced lung cancers] [0.03%]
吸烟对晚期肺癌免疫治疗疗效的影响分析
F Biney,É Giroux-Leprieur,C Daniel et al.
F Biney et al.
Introduction: Lung cancer is the leading cause of death worldwide. It occurs mainly in smokers, but also in 25% of cases in non-smokers. As regards metastatic stages, while immunotherapy has led to improved overall surviv...
Corrigendum de « Actualisation des recommandations de prise en charge des pneumonies aiguës communautaires chez l’adulte par la Société de pathologie infectieuse de langue française (SPILF) et la Société de pneumologie de langue française (SPLF). Avec le soutien de la Société de réanimation de langue française, (SRLF), de la Société française de microbi [0.03%]
关于“法国讲法语的传染病学会（SPILF）和法国讲法语的肺病学会（SPLF）对成人社区获得性肺炎管理建议进行更新。并与法国讲法语的重症监护学会（SRLF）及法国微生物学学会合作”的勘误表
A Dinh,F Barbier,J-P Bedos et al.
A Dinh et al.
R Hindré,Y Uzunhan
R Hindré
Introduction: Fibrosing interstitial lung diseases (ILD) are severe respiratory conditions that can lead to respiratory failure and death. Over the past decade, antifibrotic therapies have represented a significant therap...
L Maurier,A-L Chéné,P Hulo et al.
L Maurier et al.
Introduction: Antibody-drug conjugates (ADCs) represent a promising new therapeutic class in non-small-cell lung cancer (NSCLC) patients. Studies assessing ADC have highlighted a pulmonary toxicity profile in the form of ...
[Durable Benefit from Immunotherapy in Advanced NSCLC: The BREATH Cohort] [0.03%]
免疫治疗用于晚期NSCLC的远期疗效：BREATH研究队列数据
S Deslais,C Pierre,T Goter et al.
S Deslais et al.
Introduction: Immune checkpoint inhibitors have revolutionized the management of advanced non-small cell lung cancer (NSCLC). While the proportion of "long-term survivors" is estimated to be between 8% and 16%, this popul...